Tvardi Therapeutics (NASDAQ:TVRD) Earns Buy Rating from BTIG Research

Tvardi Therapeutics (NASDAQ:TVRD)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a research report issued on Wednesday,Benzinga reports. They currently have a $15.00 price objective on the stock. BTIG Research’s target price would indicate a potential upside of 400.00% from the stock’s current price.

Several other analysts have also recently commented on the stock. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Wall Street Zen raised shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tvardi Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $55.50.

Tvardi Therapeutics Stock Down 5.7%

Shares of NASDAQ TVRD opened at $3.00 on Wednesday. Tvardi Therapeutics has a 52-week low of $2.81 and a 52-week high of $43.65. The company has a market cap of $28.14 million, a PE ratio of -0.54 and a beta of 0.14. The firm’s 50-day moving average price is $3.78 and its 200-day moving average price is $8.96.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Tuesday, March 31st. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.23).

Institutional Investors Weigh In On Tvardi Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd purchased a new position in Tvardi Therapeutics during the 4th quarter valued at about $55,000. Quadrature Capital Ltd acquired a new stake in Tvardi Therapeutics during the fourth quarter valued at approximately $90,000. Russell Investments Group Ltd. increased its holdings in shares of Tvardi Therapeutics by 1,351.5% during the fourth quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock worth $69,000 after buying an additional 14,866 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of Tvardi Therapeutics by 534.3% during the fourth quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock worth $223,000 after purchasing an additional 43,619 shares in the last quarter. Finally, Arax Advisory Partners raised its stake in shares of Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after buying an additional 6,173 shares during the last quarter. 44.66% of the stock is owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.